Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer
- 31 August 1995
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 13 (1) , 31-44
- https://doi.org/10.1016/0169-5002(95)00478-j
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Survival of noncuratively resected lung cancerLung Cancer, 1994
- Does adjuvant chemotherapy decrease distant metastasis formation in patients with non-small cell lung cancer?Lung Cancer, 1994
- A newly developed in vitro chemosensitivity test (nuclear damage assay): Application to ovarian cancerGynecologic Oncology, 1991
- Adjuvant treatment in resected lung cancerSeminars in Surgical Oncology, 1990
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Effects of Postoperative Mediastinal Radiation on Completely Resected Stage II and Stage III Epidermoid Cancer of the LungNew England Journal of Medicine, 1986
- Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma.Journal of Clinical Oncology, 1986
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- The analysis and presentation of surgical results by actuarial methodsJournal of Surgical Research, 1974
- Maximum utilization of the life table method in analyzing survivalJournal of Chronic Diseases, 1958